Supernus Pharmaceuticals Inc SUPN:NASDAQ

Last Price$29.99NASDAQ Closing Price as of 4:00PM ET 6/24/19

Today's Change-0.86(2.79%)
Bid (Size)$29.11 (2)
Ask (Size)$30.00 (46)
Day Low / High$29.60 - 31.08
Volume465.3 K
 

View Pharmaceuticals: Other IndustryPeer Comparison as of 06/24/2019

 

Supernus Pharmaceuticals Inc ( NASDAQ )

Price: $29.99
Change: -0.86 (2.79%)
Volume: 465.3 K
4:00PM ET 6/24/2019
 
 

Madrigal Pharmaceuticals Inc ( NASDAQ )

Price: $100.97
Change: -3.89 (3.71%)
Volume: 172.3 K
3:59PM ET 6/24/2019
 
 

Prestige Consumer Healthcare Inc ( NYSE )

Price: $30.79
Change: -0.39 (1.25%)
Volume: 278.5 K
4:02PM ET 6/24/2019
 
 

Ironwood Pharmaceuticals Inc ( NASDAQ )

Price: $10.28
Change: -0.67 (6.12%)
Volume: 1.2 M
3:59PM ET 6/24/2019
 
 

Zogenix Inc ( NASDAQ )

Price: $40.76
Change: +0.14 (0.34%)
Volume: 629.2 K
3:59PM ET 6/24/2019
 

Read more news Recent News

Supernus Pharmaceuticals' Consensus Projections for Q2, 2019, and 2020 Earnings Scaled Down
3:01AM ET 5/18/2019 MT Newswires

Consensus forecasts for Supernus Pharmaceuticals Inc's (NASDAQ:SUPN, Recent Price: 33.25) Q2 ending June 30, 2019, and the full year estimates for 2019 and...

Consensus Estimates for Supernus Pharmaceuticals' 2019, 2020 Years Scaled Down
9:31AM ET 5/10/2019 MT Newswires

The 2019 and 2020 full year forecasted earnings estimates for Supernus Pharmaceuticals Inc's (NASDAQ:SUPN, Recent Price: 36.50) have been scaled down. The...

2019, and 2020 Estimates for Supernus Pharmaceuticals Reduced but Q2 Projection Increased
8:01AM ET 5/09/2019 MT Newswires

Supernus Pharmaceuticals Inc's (NASDAQ:SUPN, Recent Price: 35.66) consensus estimates for Q2 ending June 30, 2019, and the full year forecasts for 2019 and...

Supernus Q1 Results Decline YoY; Revenues Miss Street Estimate
6:35AM ET 5/08/2019 MT Newswires

Supernus Pharmaceuticals (SUPN) reported late Tuesday Q1 net profit of $0.34 per share, down from $0.49 per share in the prior year period. Capital IQ...

View all Commentary and Analysis

Stoke Therapeutics Files Proposed Terms For IPO
12:24PM ET 6/11/2019 Seeking Alpha

How To Find Undervalued Stocks In The Healthcare Sector
4:10PM ET 6/10/2019 Seeking Alpha

Supernus Is Once Again A Super Value
3:06PM ET 6/07/2019 Seeking Alpha

Supernus Pharmaceuticals (SUPN) CEO, Jack Khattar on Q1 2019 Results - Earnings Call Transcript
12:25PM ET 5/08/2019 Seeking Alpha

Company Profile

Business DescriptionSupernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD. View company web site for more details
Address1550 East Gude Drive
Rockville, Maryland 20850
Phone+1.301.838.2500
Number of Employees448
Recent SEC Filing06/24/20194
President, CEO, Secretary & DirectorJack A. Khattar
Chief Financial Officer & Senior Vice PresidentGregory S. Patrick
Vice President-Quality & Information TechnologyFrank Mottola
Chief Scientific Officer & Senior Vice PresidentPadmanabh P. Bhatt

Company Highlights

Price Open$30.99
Previous Close$30.85
52 Week Range$29.60 - 61.25
Market Capitalization$1.6 B
Shares Outstanding52.4 M
SectorHealth Technology
IndustryPharmaceuticals: Other
Next Earnings Announcement08/06/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings16.15
Earnings per Share$1.90
Beta vs. S&P 500N/A
Revenue$408.9 M
Net Profit Margin25.49%
Return on Equity23.60%

Analyst Ratings as of 06/14/2019

Buy
7
Overweight
0
Hold
1
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset